TrialCancer medicine2023

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.

Masahiro Iwasaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.